http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2403141-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40b25e221408b9cde608f61b237aef22 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q17-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D251-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D251-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-4966 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D251-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate | 2003-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9bba11a80a4e1932d27c16620d413c7f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_133ed55ebac8bc71b602fbe32000d1a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8a149c794e17cddf75718b5acfd29c7 |
| publicationDate | 2013-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2403141-T3 |
| titleOfInvention | 2,4-diamino-1,3,5-triazine derivative |
| abstract | A dihydrotriazine compound represented by 1 A dihydrotriazine compound represented by the general formula (1a): where R1 represents (i the general formula (1a): where R1 represents (i) a phenyl group or a phenylalkyl group, each ) a phenyl group or a phenylalkyl group, each of which is substituted with from 1 to 3 substitute of which is substituted with from 1 to 3 substituents selected from the group consisting of aluents selected from the group consisting of C 1-6 alkoxy, hydroxy , halogen atom, haloC1-6alkyloxyloxy, hydroxy, halogen atom, haloC1-6alkyl, C1-6alkyl, sulfonamido group and C1-6 haloalkoxy, C1-6alkyl, sulfonamido group, and C1-6alkoxy, (ii) a naphthyl group or a C1-6 naphthylalkyl group, (ii) a naphthyl group or a naphthylalkyl group, (iii) a heterocyclic group, an alkyloyl group, (iii) a heterocyclic group, a heterocyclic alkyl group or a heterocyclic heterocyclic aminoalkyl group or a aminoalkyl group or heterocyclic, (iv) an alkyl group of 1 to 16 carbon atoms, (iv) an alkyl group of 1 to 16 carbon atoms, or (v) a cycloalkyl group or a cyclone group, or (v) a cycloalkyl group or a cycloalkyl alkyl group; R1 'represents a hydroalkyl alkyl atom; R1 'represents a hydrogen atom attached to the nitrogen atom at position 1 or not attached to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring; R21 represents un3 of the dihydrotriazine ring; R21 represents an alkyl group of 7 to 16 carbon atoms; R3 and R alkyl group of 7 to 16 carbon atoms; R3 and R4 represent that R3 is a hydrogen atom or un4 represent that R3 is a hydrogen atom or a methyl group, and R4 is a hydrogen atom or a methyl group, and R4 is a hydrogen atom or a group methyl; and the hatched line indicates that the posicgrupomethyl; and the hatched line indicates that the position of a double bond is between 1 and 2 or between 2 and the ion of a double bond is between 1 and 2 or between 2 and 3, or a tautomer thereof or a pharmaceutical salt3, or a tautomer thereof or a pharmaceutically acceptable salt thereof of the same type acceptable therein |
| priorityDate | 2002-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 397.